Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aktuelle Urologie·2026
Same author

Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.

BJU international·2026
Same author

[From limited options to individualized strategies: advances in the treatment of bladder cancer].

Urologie (Heidelberg, Germany)·2026
Same author

[Critical self-assessment as an instrument to optimize surgical strategies in the management of upper urinary tract urothelial cancer].

Urologie (Heidelberg, Germany)·2026
Same author

<i>NECTIN4</i> Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

European urology open science·2026
Same author

[Multidisciplinary cancer therapy-more important than ever].

Urologie (Heidelberg, Germany)·2026

Related Experiment Video

Updated: Dec 12, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins.

Tim Nestler1, Maike Wittersheim2, Stephan Schaefer2

  • 1Department of Urology, University Hospital of Cologne, Cologne, Germany, tim.nestler@uk-koeln.de.

Urologia Internationalis
|August 14, 2020
PubMed
Summary

Identifying radioresistance in prostate cancer (PCA) is crucial. This study found androgen receptor (AR) and AKR1C3 protein expression similar in radio-recurrent PCA and high-risk PCA, suggesting they can predict treatment response.

Keywords:
Aldo-keto reductase family 1 member C3Androgen receptorProstate cancerProtein expressionRadioresistance

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.9K

Related Experiment Videos

Last Updated: Dec 12, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.9K

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Prostate cancer (PCA) relapse after radiotherapy is common.
  • Predicting radioresistance before treatment remains a challenge.
  • This study investigates protein expression differences in PCA patients.

Purpose of the Study:

  • To compare protein expression profiles of radio-recurrent PCA with primary prostatectomy patients.
  • To identify potential biomarkers for predicting radioresistance in PCA.
  • To hypothesize that radio-recurrent PCA shares protein expression with high-risk PCA.

Main Methods:

  • Analyzed protein expression in 31 radio-recurrent PCA patients and 94 primary prostatectomy patients (high-risk vs. low-risk Gleason).
  • Utilized immunohistochemistry with 15 antibodies linked to PCA radioresistance.
  • Validated selected markers using ELISA in serum.

Main Results:

  • Androgen receptor (AR) overexpression was high in radio-recurrent PCA (89.7%) and high-risk PCA (87.8%), but lower in low-risk PCA (67.3%).
  • Aldo-keto reductase family 1 member C3 (AKR1C3) expression mirrored that of radio-recurrent PCA and high Gleason pattern PCA (4 and 5).
  • ELISA results supported the findings for AR and AKR1C3.

Conclusions:

  • This is the first study to explore protein markers for predicting PCA radioresistance.
  • AR and AKR1C3 show promise as biomarkers for stratifying PCA patients for radiotherapy.
  • These markers could aid in personalized treatment strategies for prostate cancer.